In our study, we established a prognostic risk model based on three genes (NT5E, UPP1 and DPYS) found to be associated with GC pyrimidine metabolism and demonstrated that this prognostic risk model is a reliable and independent clinical feature of GC. The gene discussed is DPYS; the disease is gastric cancer.